|
Mr. Tullman co-founder, President and CEO of Ception Therapeutics, spearheaded the merger of Fulcrum's early pipeline and discovery engine with Ception's late phase anti-inflammatory program in December 2005. Prior to the formation of the new company, he co-founded Trigenesis Therapeutics, Inc. and served as the Chief Business Officer prior to the company's sale to Reddy Laboratories. Steve began his professional career in the pharmaceutical industry at SmithKline Beecham (now GlaxoSmithKline), working for the company for over fourteen years he accumulated broad industry experience in finance, sales, marketing, research and development. Steve held key positions including the head of GSK's Global Commercial Strategy for the Musculoskeletal, Inflammation and Dermatology Therapeutic Areas including all assets from discovery through marketed products. He also led Global Commercial Strategy as Director for Respiratory New Product Development, International Marketing Director for the Philippines, Associate Director for Anti-infective Products and Global Brand Director for Bactroban®, Senior Global Marketing Research Manager and Manager of Business Development Analysis. He was invited to join the company's Management Executive Training Program, which included positions in U.S. pharmaceutical and vaccine hospital sales, regulatory affairs, commercial information systems and South America finance & marketing. He has worked overseas, living in the UK and in South East Asia and has many years of overall global commercial development responsibility. Steve is also a co-founder and Director of the PreSun® Company, a privately held dermatology company, and he is a board member of Euromed Inc., a manufacturer and marketer of wound care dressings. Steve received his Bachelors of Science Degree from Rutgers University in New Jersey. | 